Lymphoma

Introduction

Lymphoma is a cancer that originates in lymphocytes—white blood cells of the immune system found in lymph nodes, spleen, bone marrow, and lymphatic tissue throughout the body. When lymphocytes become malignant, they multiply uncontrollably and form tumors.

More than 70 subtypes exist, grouped mainly into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Hodgkin lymphoma features Reed-Sternberg cells and often has a very high cure rate. NHL is more common and more heterogeneous, ranging from slow-growing indolent forms to aggressive ones requiring urgent treatment.

Symptoms can be subtle—painless swollen lymph nodes, night sweats, fevers, and weight loss—leading many patients to delay evaluation. Advances in chemotherapy, immunotherapy, targeted drugs, and radiation have dramatically improved outcomes.

This page explains lymphoma types, symptoms, diagnosis, staging, treatment, and how lymphoma differs from the broader category of lymphoproliferative disorders.

Overview

Lymphoma specifically denotes malignant lymphoid cancer confirmed on biopsy. Lymphoproliferative disorders is a wider term that includes both benign reactive expansions and malignant conditions such as lymphoma and lymphocytic leukemia.

Hodgkin lymphoma accounts for about 10% of cases, peaks in young adults and older adults, and spreads in predictable nodal patterns. NHL accounts for roughly 90%, includes dozens of subtypes classified by B-cell or T-cell origin, and varies widely in behavior and prognosis.

Definitive diagnosis requires excisional lymph node biopsy or adequate tissue sampling reviewed by an expert pathologist. Staging with PET-CT and bone marrow assessment guides treatment intensity.

• Malignant cancer of lymphocytes within the lymphatic system
• Two main groups: Hodgkin lymphoma (Reed-Sternberg cells) and non-Hodgkin lymphoma
• Most common presenting sign: painless enlarged lymph node in neck, armpit, or groin
• "B symptoms": fever, drenching night sweats, unexplained weight loss over 10% in six months
• Risk factors include EBV, HIV, autoimmune disease, immunosuppressant drugs, family history
• Biopsy is mandatory for diagnosis—blood tests alone are insufficient
• Staging I–IV describes extent of spread; guides chemotherapy and radiation plans
• Many Hodgkin and aggressive NHL subtypes are curable; indolent NHL is often managed long-term

What happens in the body

Lymphoma develops when genetic mutations in lymphocytes disable normal growth controls, allowing uncontrolled proliferation and resistance to apoptosis. Malignant cells accumulate in lymph nodes and can infiltrate bone marrow, liver, spleen, and extranodal sites.

Hodgkin lymphoma Reed-Sternberg cells secrete cytokines causing B symptoms. NHL subtypes arise at different maturation stages of B or T cells, explaining varied growth rates, marker profiles, and treatment responses.

• DNA mutations transform normal lymphocytes into malignant clones
• Malignant cells displace normal lymphoid architecture in nodes and organs
• Cytokine release from tumor cells causes fever, sweats, and cachexia (B symptoms)
• Extranodal spread to stomach, brain, skin, or bone occurs in specific NHL subtypes

Signs and symptoms

Symptoms may be localized or systemic depending on subtype and stage:

• Painless swollen lymph node in neck, armpit, or groin persisting more than two weeks
• Unexplained fever that comes and goes
• Drenching night sweats requiring change of clothes or bedding
• Unintentional weight loss exceeding 10% of body weight over six months
• Persistent fatigue and reduced energy
• Generalized itching (pruritus) without rash—more common in Hodgkin lymphoma
• Abdominal pain, fullness, or swelling from enlarged spleen or liver
• Chest pain, cough, or shortness of breath from mediastinal mass
• Bone pain if marrow or bone is involved
• Skin lumps or rash in cutaneous lymphoma subtypes
• Neurologic symptoms if central nervous system is involved
• Alcohol-induced pain at lymph node site—rare but suggestive of Hodgkin lymphoma
• No symptoms except enlarged node in early limited-stage disease

Causes and risk factors

Most lymphomas have no single known cause; recognized risk factors include:

• Acquired genetic mutations in lymphocytes—exact triggers often unknown
• Epstein-Barr virus linked to some Hodgkin and NHL subtypes
• HIV/AIDS and other immunodeficiency states
• Autoimmune diseases: rheumatoid arthritis, lupus, Sjögren syndrome
• Immunosuppressant drugs after organ transplant
• Helicobacter pylori associated with gastric MALT lymphoma
• HTLV-1 virus linked to adult T-cell leukemia/lymphoma
• Family history of lymphoma—modest increased risk
• Chemical exposures (benzene, pesticides) and prior high-dose radiation
• Age—NHL risk rises with age; Hodgkin has bimodal peaks in young and older adults

Diagnosis and evaluation

Tissue diagnosis and staging define the treatment pathway:

• Excisional lymph node biopsy preferred over fine needle aspiration for initial diagnosis
• Pathology with immunohistochemistry to classify Hodgkin vs. NHL subtype
• Complete blood count and lactate dehydrogenase (LDH) as prognostic markers
• PET-CT scan for staging and detection of metabolically active disease
• Bone marrow aspiration and biopsy in selected subtypes and stages
• Flow cytometry on blood or tissue when circulating involvement suspected
• HIV and hepatitis screening before chemotherapy when risk factors present
• Lumbar puncture in subtypes at risk for central nervous system involvement

Treatment and management

Treatment is highly subtype-specific and stage-dependent:

• Chemotherapy combinations such as ABVD for Hodgkin lymphoma or R-CHOP for common B-cell NHL
• Rituximab (anti-CD20) for B-cell lymphomas expressing CD20
• Radiation therapy for early-stage Hodgkin lymphoma or localized NHL
• Immunotherapy including checkpoint inhibitors for relapsed or selected NHL subtypes
• Targeted agents: BTK inhibitors, BCL-2 inhibitors, proteasome inhibitors by subtype
• CAR-T cell therapy for relapsed or refractory aggressive B-cell lymphomas
• Autologous or allogeneic stem cell transplant for relapsed or high-risk disease
• Watchful waiting for asymptomatic indolent NHL without treatment indication
• Treatment of associated infections (H. pylori eradication for gastric MALT lymphoma)
• Supportive care: growth factors, infection prophylaxis, fertility preservation counseling

Prevention, self-care, and lifestyle

Not every condition is fully preventable, but the steps below may lower risk or recurrence:

• No routine screening exists for lymphoma in the general population
• Treat chronic H. pylori infection when diagnosed
• Manage HIV with antiretroviral therapy to reduce lymphoma risk
• Limit unnecessary immunosuppression and discuss cancer risk with transplant teams
• Maintain general health—benefits overall though no proven lymphoma-specific prevention

Possible complications

Delay, missed care, or unsafe self-medication can raise the chance of complications in some cases:

• Disease progression and organ compromise from untreated lymphoma
• Chemotherapy and radiation side effects: infection, infertility, secondary cancers, cardiac toxicity
• Transformation of indolent NHL to aggressive subtype
• Relapse after initial remission requiring salvage therapy or transplant
• Paraneoplastic syndromes and immune complications in some subtypes

When to see a doctor or seek emergency care

Seek prompt medical advice or emergency care if any of the following apply—it is safer not to wait and see:

• Painless lymph node swelling lasting more than two weeks without infection
• Persistent fever, night sweats, or unexplained weight loss
• Worsening cough, chest pain, or shortness of breath with lymphadenopathy
• Abdominal swelling, early satiety, or new severe fatigue
• Any B symptoms in a person with known immunodeficiency or autoimmune disease

Living with the condition

Survivorship care includes monitoring for relapse, managing late effects of chemotherapy and radiation, and addressing fatigue and emotional health.

Keep a personal treatment summary with subtype, stage, drugs received, and recommended follow-up imaging schedule.

Indolent NHL may be managed as a chronic condition for many years—regular hematology follow-up is essential even when not on active treatment.

Frequently asked questions

Is lymphoma the same as lymphoproliferative disorder?

Lymphoma is a malignant lymphoproliferative disorder—a cancer of lymphocytes. The broader term also includes benign reactive expansions and leukemias such as CLL.

Is lymphoma curable?

Many Hodgkin and aggressive NHL subtypes are curable. Indolent NHL is often controlled long-term rather than permanently eradicated.

How is lymphoma different from lymphocytosis?

Lymphocytosis is a high lymphocyte count on blood tests, sometimes from infection or CLL. Lymphoma is a tissue-diagnosed cancer that may or may not show lymphocytosis.

What are B symptoms?

Fever, drenching night sweats, and unintentional weight loss of more than 10% over six months—they indicate more advanced or active disease and affect staging.

Does a swollen lymph node always mean lymphoma?

No. Most enlarged nodes result from infection. Persistent painless enlargement without infection warrants biopsy.

What is the 5-year survival rate?

Hodgkin lymphoma exceeds 80–90% in many cases. NHL varies widely by subtype—from very favorable for some slow-growing types to around 60% for common aggressive forms.

Important caution

Lymphoma is a confirmed malignant cancer of lymphocytes—not a vague immune abnormality—and requires tissue biopsy for diagnosis.

Persistent painless lymphadenopathy, B symptoms, or unexplained systemic illness should prompt hematology referral without delay.

Modern combined-modality therapy cures many patients; subtype-accurate diagnosis is the foundation of effective treatment.